<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938235</url>
  </required_header>
  <id_info>
    <org_study_id>MB001-001</org_study_id>
    <secondary_id>9427-D0416-21C</secondary_id>
    <nct_id>NCT01938235</nct_id>
  </id_info>
  <brief_title>Exenatide for Myocardial Protection During Reperfusion Study</brief_title>
  <acronym>EMPRES</acronym>
  <official_title>Exenatide for Myocardial Protection During Reperfusion Study: A Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effect of exenatide on myocardial injury in patients undergoing
      emergent percutaneous coronary intervention (PCI) for ST segment elevation myocardial
      infarction or heart attack (STEMI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II randomized, double-blind, placebo-controlled study of patients with STEMI.
      Those who agree to participate will be immediately randomized to one of two groups: a 24-h
      infusion of exenatide; or a 24 h infusion of placebo. We will assess the ability of exenatide
      to reduce ischemic injury. This study will serve as safety evaluation study as well as a
      pilot for a larger multicentre trial powered for clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of final infarct size at 3 months over area at risk at 72 hours post randomization (using cMRI)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular global and regional LV systolic ejection fraction</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular global and regional LV systolic ejection fraction</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular volume</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular volume</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size/area of risk (measured by cMRI)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial enzyme levels (troponin I and CK-MB)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment elevation resolution (measured by ECG)</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment elevation resolution (measured by ECG)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment elevation resolution (measured by ECG)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment elevation resolution (measured by ECG)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic myocardial blush score</measure>
    <time_frame>At the time of the PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose concentration</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose concentration</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose concentration</measure>
    <time_frame>16 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose concentration</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose concentration</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker levels (interleukin-6, interleukin-10, TNF-alpha)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP blood levels</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (heart attack)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of extent of heart failure (NYHA classification)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of extent of heart failure (NYHA classification)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (defined as a combined outcome of death, recurrent myocardial infarction, stroke, and unplanned repeat revascularization)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent myocardial infarction (heart attack)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned repeat revascularization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of heart failure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiogenic shock</measure>
    <time_frame>During index hospitalization (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose &lt; 3.0 mmol/L</measure>
    <time_frame>During index hospitalization (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension (defined as SBP &lt;90 mmHg)</measure>
    <time_frame>During index hospitalization (up to 6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>o Exenatide at a dose of 1.5 µg IV over 30 min followed by 1.2 µg/hr IV for 1.5 h (Rate1), followed by 1.9 µg/hr IV* for 22 h (Rate 2)
*Once the creatinine clearance is available, if the value is &lt;60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is &lt;60 mL/min.
If the creatinine clearance is &lt;30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.
A bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>o Placebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours*.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Intravenous bolus and 24-hour infusion of exenatide</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous bolus and 24-hour infusion of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission for primary PCI for STEMI, with enrollment within 12 hours of onset of
             symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥1mm in 2
             or more limb leads, or ≥2mm in 2 or more precordial leads, or new onset LBBB)
             associated with acute chest pain or an elevation of cardiac enzymes.

          -  Antegrade TIMI 0 or 1 prior to PCI in the infarct-related artery

          -  Age ≥18 years

        Exclusion Criteria:

          -  Symptomatic hypoglycemia (serum glucose &lt;3.3 µmol/L; 60 mg/dl)

          -  Diabetes mellitus requiring insulin therapy

          -  Diabetic ketoacidosis

          -  Coronary anatomy warranting emergent coronary artery bypass graft surgery

          -  Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute
             severe mitral regurgitation)

          -  Need for hemodialysis

          -  Malignancy, HIV, or central nervous system disorder

          -  Cardiopulmonary resuscitation &gt;15 min and compromised level of consciousness.

          -  Cardiogenic shock

          -  Current participation in any research study involving investigational drugs or devices

          -  Inability to give informed consent

          -  Inability to safely undergo cMRI (presence of cardiac pacemaker, implanted cardiac
             defibrillator, aneurysm clips, carotid artery vascular clamp, neurostimulator,
             implanted drug infusion device, bone growth/fusion stimulator, cochlear, otologic, or
             ear implant, severe claustrophobia)

          -  Women of childbearing potential who are known to be pregnant or lactating or who have
             a positive pregnancy test on admission

          -  History of pancreatitis

          -  Known end stage renal failure or known eGFR &lt;30 mL/min

          -  Currently taking exenatide (Byetta, Bydureon), liraglutide (Victoza), or any other
             GLP-1 agonist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Dzavik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Val Panzov, MD</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>7125</phone_ext>
    <email>panzovV@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Giamou, BSc</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>7889</phone_ext>
    <email>giamoum@smh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Manasterski</last_name>
      <phone>403-210-8548</phone>
      <email>linda.manasterski@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Faisal Al Qoofi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Kvill</last_name>
      <phone>780-735-5255</phone>
      <email>linda.kvill@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Neil Brass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Welsh</last_name>
      <phone>780-407-3572</phone>
      <email>suzanne.welsh@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Robert Welsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - General Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya Brons</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>44602</phone_ext>
      <email>bronsson@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Sanjit Jolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mistre Alemayehu</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>35625</phone_ext>
      <email>mistre.alemayehu@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Shahar Lavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Robbins</last_name>
      <phone>905-235-5966</phone>
      <email>kim.yorkpci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Warren Cantor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneet Khurana</last_name>
      <phone>416-480-4520</phone>
      <email>suneet.khurana@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Mina Madan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigita Zile</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>4130</phone_ext>
      <email>zileb@smh.ca</email>
    </contact>
    <investigator>
      <last_name>John J Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Asif</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>4969</phone_ext>
      <email>nadia.asif@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vladimir Dzavik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Quebec (Hopital Laval)</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Jadin</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3007</phone_ext>
      <email>michele.jadin@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Olivier Bertrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Vladimír Džavík</investigator_full_name>
    <investigator_title>Director, Research and Innovation in Interventional Cardiology and Cardiac Intensive Care, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Reperfusion injury</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

